Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CONZIP vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Moderate to moderately severe pain,Pain management in adults
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal elimination half-life: 3-4 hours for tramadol, 5-9 hours for M1 metabolite; clinically, dosing interval is 4-6 hours
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Tramadol: hepatic via CYP2D6 and CYP3A4 to active M1 metabolite; acetaminophen: hepatic via conjugation (glucuronidation, sulfation) and CYP2E1 (minor).
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
~60% renal (unchanged drug and glucuronide conjugates), ~35% fecal
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
~20% bound to plasma proteins (primarily albumin)
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
3.9 L/kg (tramadol), indicating extensive tissue distribution
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Oral: 75% (immediate-release); extended-release: ~100% relative to immediate-release
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
For creatinine clearance (Cr Cl) 60-89 m L/min: no adjustment. For Cr Cl 30-59 m L/min: reduce dose by 30% (e.g., start 70 mg daily). For Cr Cl 15-29 m L/min: reduce dose by 50% (e.g., start 50 mg daily). For Cr Cl <15 m L/min: not recommended. Hemodialysis: administer dose after dialysis on dialysis days; reduce dose by 70%.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
For Child-Pugh Class A (mild): no adjustment. For Child-Pugh Class B (moderate): reduce dose by 50% (e.g., start 50 mg daily). For Child-Pugh Class C (severe): not recommended (or maximum 50 mg daily with caution).
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Safety and efficacy not established in pediatric patients (<18 years). No recommended dosage.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
For patients ≥65 years: initiate at 100 mg daily. Use caution and monitor for confusion and sedation. Consider reducing dose to 50 mg daily if tolerability issues arise.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); ultra-rapid metabolism of tramadol to O-desmethyltramadol (M1) in CYP2D6 poor metabolizers leading to toxicity; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Respiratory depression; seizure risk (especially with CNS depressants, MAOIs, SSRIs, SNRIs); serotonin syndrome; increased intracranial pressure; severe hypotension; head injury; acute abdominal conditions; renal/hepatic impairment; elderly; debilitated patients; drug dependence; withdrawal; pregnancy; nursing mothers; CYP2D6 ultrarapid metabolizers; concomitant use with alcohol or other CNS depressants.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Hypersensitivity to tramadol, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; gastrointestinal obstruction (including paralytic ileus); use of MAOIs within 14 days; treatment of acute severe asthma exacerbation; concurrent use of linezolid; known history of prolonged QT interval or QT prolongation risk factors (tramadol component); severe hepatic impairment (acetaminophen).
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Grapefruit and grapefruit juice may increase tramadol levels by inhibiting CYP3A4 metabolism. Avoid excessive caffeine as it may increase seizure risk. Food does not significantly affect absorption; may be taken with or without food.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
CONZIP (tramadol hydrochloride) is FDA Pregnancy Category C. In first trimester, cross-reactivity with opioid receptors raises concern for neural tube defects based on animal studies; human data limited but not excluded. In second and third trimesters, prolonged use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS). Near term, use may lead to respiratory depression in the neonate.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Tramadol is excreted into breast milk. M/P ratio approximately 0.94 for tramadol and 0.8 for O-desmethyltramadol (active metabolite). Infant exposure estimated at 2.24% of maternal weight-adjusted dose. May cause drowsiness or poor feeding in infants; not recommended during breastfeeding unless benefit outweighs risk.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
No specific dose adjustment guidelines; pregnancy may increase clearance of tramadol, potentially reducing efficacy, but safety data insufficient to recommend dose increase. Use lowest effective dose for shortest duration. Chronic use may require slow taper to prevent withdrawal.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
CONZIP (tramadol hydrochloride) is a centrally acting opioid analgesic with additional serotonin and norepinephrine reuptake inhibition. It has a lower risk of respiratory depression compared to typical opioids but carries risks of seizures, especially in patients with epilepsy, head trauma, or those taking SSRIs, SNRIs, or MAOIs. CYP2D6 poor metabolizers may have reduced efficacy. Do not exceed 400 mg/day (300 mg in elderly >75 years). Avoid sudden discontinuation to prevent withdrawal syndrome.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol, sedatives, and other CNS depressants as they increase risk of severe drowsiness and respiratory depression.,Do not stop suddenly; taper dose under medical supervision to prevent withdrawal symptoms.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how you react.,Risk of serotonin syndrome when combined with other serotonergic drugs; report symptoms like agitation, high fever, or muscle twitching.,If you have a history of seizures, inform your doctor; tramadol may lower seizure threshold.,Swallow tablets whole; do not crush, chew, or split extended-release tablets.,Store in original container away from moisture and heat.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CONZIP vs ALFENTANIL, answered by our medical review team.
CONZIP is a Opioid Analgesic that works by Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CONZIP and ALFENTANIL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CONZIP is: 100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CONZIP and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CONZIP is classified as Category C. CONZIP (tramadol hydrochloride) is FDA Pregnancy Category C. In first trimester, cross-reactivity with opioid receptors raises concern for neural tube defects based on animal studi. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.